Advanced search

Vol 25, No 4 (2018)
Position Paper
Published online: 2018-09-12

open access

View PDF Download PDF file
Page views 7704
Article views/downloads 2784
Get Citation

Connect on Social Media

Connect on Social Media

Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

Anna Tomaszuk-Kazberuk12, Lukasz Kołtowski13, Paweł Balsam13, Marek Koziński14, Agnieszka Kapłon-Cieślicka13, Karolina Kupczyńska15, Justyna Domienik-Karłowicz16, Anna Budaj-Fidecka13, Piotr Buszman178, Maciej Wybraniec19, Paweł Burchardt11011, Błażej Michalski15, Miłosz J. Jaguszewski112
DOI: 10.5603/CJ.2018.0080
Pubmed: 30211927
Cardiol J 2018;25(4):423-440.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393.
    CrossRefPubMed
  2. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15(5): 625–651.
    CrossRef
  3. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
    CrossRefPubMed
  4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
    CrossRef
  5. Barnes GD, Ageno W, Ansell J, et al. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost. 2015; 13(6): 1154–1156.
    CrossRef
  6. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
    CrossRefPubMed
  7. Lip G, Collet J, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). EP Europace. 2017; 19(11): 1757–1758.
    CrossRef
  8. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2015; 132(8): 624–632.
    CrossRefPubMed
  9. Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation. 2016; 134(8): 589–598.
    CrossRefPubMed
  10. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014; 35(47): 3377–3385.
    CrossRefPubMed
  11. De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2017; 69(11): 1372–1382.
    CrossRefPubMed
  12. Pan KL, Singer DE, Ovbiagele B, et al. Effects of non-vitamin k antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017; 6(7).
    CrossRefPubMed
  13. Noseworthy PA, Yao X, Shah ND, et al. Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. J Am Coll Cardiol. 2016; 67(25): 3020–3021.
    CrossRefPubMed
  14. Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol. 2017; 248: 232–238.
    CrossRefPubMed
  15. Lane D, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015; 17(12): 1747–1769.
    CrossRef
  16. Heidbuchel H, Berti D, Campos M, et al. Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thromb J. 2015; 13: 22.
    CrossRefPubMed
  17. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
    CrossRefPubMed
  18. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). , 2018. Eur Heart J. 2018; 39(3): 213–260.
    CrossRefPubMed
  19. Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1): 179.
    CrossRefPubMed
  20. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016; 151(6): 1105–1112.e10.
    CrossRefPubMed
  21. Di Minno A, Spadarella G, Spadarella E, et al. Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. Thromb Res. 2015; 136(6): 1074–1081.
    CrossRefPubMed
  22. Chan E, Lau W, Leung W, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015; 149(3): 586–595.e3.
    CrossRef
  23. Lane DA, Barker RV, Lip GYH. Best practice for atrial fibrillation patient education. Curr Pharm Des. 2015; 21(5): 533–543.
    PubMed
  24. Lane DA, Wood K. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation. 2015; 131(16): e412–e415.
    CrossRefPubMed
  25. Gallagher C, Elliott AD, Wong CX, et al. Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart. 2017; 103(24): 1947–1953.
    CrossRefPubMed
  26. Carter L, Gardner M, Magee K, et al. An Integrated Management Approach to Atrial Fibrillation. J Am Heart Assoc. 2016; 5(1).
    CrossRefPubMed
  27. Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet. 2017; 390(10105): 1873–1887.
    CrossRefPubMed
  28. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017; 117(2): 209–218.
    CrossRefPubMed
  29. Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018; 16(2): 209–219.
    CrossRefPubMed
  30. Vinereanu D, Lopes RD, Bahit MC, et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet. 2017; 390(10104): 1737–1746.
    CrossRefPubMed
  31. Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015; 313(14): 1443–1450.
    CrossRefPubMed
  32. Santo K, Richtering SS, Chalmers J, et al. Mobile phone apps to improve medication adherence: a systematic stepwise process to identify high-quality apps. JMIR Mhealth Uhealth. 2016; 4(4): e132.
    CrossRefPubMed
  33. Guo Y, Chen Y, Lane DA, et al. Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF app trial. Am J Med. 2017; 130(12): 1388–1396.e6.
    CrossRefPubMed
  34. Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012; 29(8): 675–690.
    CrossRefPubMed
  35. Weeda ER, Coleman CI, McHorney CA, et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis. Int J Cardiol. 2016; 216: 104–109.
    CrossRefPubMed
  36. Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012; 18(3): 139–146.
    PubMed
  37. Ruff CT, Giugliano RP, Braunwald E, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014; 64(6): 576–584.
    CrossRefPubMed
  38. Patel MR, Helkamp AS, Lokhnygina y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013; 61(6): 651–658.
    CrossRefPubMed
  39. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J. 2015; 169(1): 25–30.
    CrossRefPubMed
  40. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011; 338(1): 372–380.
    CrossRefPubMed
  41. Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013; 13(5): 331–342.
    CrossRefPubMed
  42. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013; 76(3): 455–466.
    CrossRefPubMed
  43. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010; 38(3): 448–58.
    CrossRefPubMed
  44. Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014; 53(1): 1–16.
    CrossRefPubMed
  45. Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015; 79(5): 838–846.
    CrossRefPubMed
  46. Parasrampuria DA, Mendell J, Shi M, et al. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016; 82(6): 1591–1600.
    CrossRefPubMed
  47. Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor xa. Am J Cardiovasc Drugs. 2016; 16(2): 119–127.
    CrossRefPubMed
  48. Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016; 126: 98–101.
    CrossRefPubMed
  49. Stöllberger C. Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol. 2017; 10(11): 1191–1202.
    CrossRefPubMed
  50. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008; 36(2): 386–399.
    CrossRefPubMed
  51. Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47(1): 47–59.
    CrossRefPubMed
  52. Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011; 51(5): 687–694.
    CrossRefPubMed
  53. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011; 9(11): 2168–2175.
    CrossRefPubMed
  54. Frost C, Shenker A, Gandhi MD, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014; 78(4): 877–885.
    CrossRefPubMed
  55. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385(9984): 2288–2295.
    CrossRefPubMed
  56. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016; 134(1): 24–36.
    CrossRefPubMed
  57. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014; 129(9): 961–970.
    CrossRefPubMed
  58. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32(19): 2387–2394.
    CrossRefPubMed
  59. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012; 33(22): 2821–2830.
    CrossRefPubMed
  60. Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2016; 1(4): 451–460.
    CrossRefPubMed
  61. Fordyce CB, Piccini JP, Patel MR, et al. On-Treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation. 2016; 134(1): 37–47.
    CrossRefPubMed
  62. Khoury T, Ayman AR, Cohen J, et al. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. Digestion. 2016; 93(2): 149–159.
    CrossRefPubMed
  63. Lauschke VM, Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016; 17(10).
    CrossRefPubMed
  64. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
    CrossRefPubMed
  65. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
    CrossRefPubMed
  66. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.
    CrossRefPubMed
  67. Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013; 76(1): 89–98.
    CrossRefPubMed
  68. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012; 130(6): 956–966.
    CrossRefPubMed
  69. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107(5): 985–997.
    CrossRefPubMed
  70. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50(7): 743–753.
    CrossRefPubMed
  71. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78(4): 412–421.
    CrossRefPubMed
  72. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 1116–1127.
    CrossRefPubMed
  73. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100(9): 1419–1426.
    CrossRefPubMed
  74. Douxfils J, Chatelain C, Chatelain B, et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013; 110(2): 283–294.
    CrossRefPubMed
  75. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015; 39(3): 288–294.
    CrossRefPubMed
  76. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017; 70(24): 3042–3067.
    CrossRefPubMed
  77. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012; 125(4): 417–420.
    CrossRefPubMed
  78. Kaess BM, Ammar S, Reents T, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol. 2015; 115(1): 47–51.
    CrossRefPubMed
  79. Mani H, Herth N, Kasper A, et al. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit. 2014; 36(5): 624–631.
    CrossRefPubMed
  80. Godier A, Dincq AS, Martin AC, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017; 38(31): 2431–2439.
    CrossRefPubMed
  81. Auer J, Huber K, Granger CB. Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? Eur Heart J. 2017; 38(31): 2440–2443.
    CrossRefPubMed
  82. Peetermans M, Pollack C, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol (Phila). 2016; 54(8): 644–646.
    CrossRefPubMed
  83. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017; 377(5): 431–441.
    CrossRefPubMed
  84. Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor xa inhibitors. N Engl J Med. 2016; 375(12): 1131–1141.
    CrossRefPubMed
  85. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371(22): 2141–2142.
    CrossRefPubMed
  86. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011; 9(9): 1705–1712.
    CrossRefPubMed
  87. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734): 23–32.
    CrossRefPubMed
  88. Poeran J, Rasul R, Suzuki S, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014; 349: g4829.
    PubMed
  89. Tomaszuk-Kazberuk A, Łopatowska P, Młodawska E, et al. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm. Pol Arch Intern Med. 2017; 127(1): 68–70.
    CrossRefPubMed
  90. Pruszczyk P, Tomaszuk-Kazberuk A, Słowik A, et al. Management of bleeding or urgent interventions in patients treated with direct oral anticoagulants: 2017 recommendations for Poland. Pol Arch Intern Med. 2017; 127(5): 343–351.
    CrossRefPubMed
  91. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014; 124(6): 955–962.
    CrossRefPubMed
  92. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012; 126(3): 343–348.
    CrossRefPubMed
  93. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011; 42(12): 3594–3599.
    CrossRefPubMed
  94. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012; 10(9): 1841–1848.
    CrossRefPubMed
  95. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012; 116(1): 94–102.
    CrossRefPubMed
  96. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124(14): 1573–1579.
    CrossRefPubMed
  97. Song Y, Wang Z, Perlstein I, et al. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. J Thromb Haemost. 2017; 15(11): 2125–2137.
    CrossRefPubMed
  98. Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014; 12(9): 1428–1436.
    CrossRefPubMed
  99. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015; 131(1): 82–90.
    CrossRefPubMed
  100. Gorczyca-Michta I, Wożakowska-Kapłon B. Percutaneous left atrial appendage occlusion: New perspectives for the method. Cardiol J. 2017; 24(5): 554–562.
    CrossRefPubMed
  101. Albaladejo P, Samama CM, et al. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology. 2017; 127(1): 111–120.
    CrossRefPubMed
  102. Majeed A, Ågren A, Holmström M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017; 130(15): 1706–1712.
    CrossRef
  103. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015; 46(7): 2032–2060.
    CrossRefPubMed
  104. Kuramatsu J, Gerner S, Schellinger P, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015; 313(8): 824–836.
    CrossRef
  105. Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018; 83(1): 186–196.
    CrossRefPubMed
  106. Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection. Int J Stroke. 2017; 12(4): 383–391.
    CrossRefPubMed
  107. Purrucker JC, Haas K, Rizos T, et al. Coagulation testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants. Stroke. 2017; 48(1): 152–158.
    CrossRefPubMed
  108. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3): e46–e110.
    CrossRefPubMed
  109. Tse DM, Young L, Ranta A, et al. Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab. J Neurol Neurosurg Psychiatry. 2018; 89(5): 549–550.
    CrossRefPubMed
  110. Xian Y, Federspiel JJ, Hernandez AF, et al. Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin k antagonist oral anticoagulants before stroke. Circulation. 2017; 135(11): 1024–1035.
    CrossRefPubMed
  111. Seiffge DJ, Traenka C, Polymeris AA, et al. Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels: experience with a standard operation procedure in clinical practice. J Stroke. 2017; 19(3): 347–355.
    CrossRefPubMed
  112. Drouet L, Bal Dit Sollier C, Steiner T, et al. Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used? Int J Stroke. 2016; 11(7): 748–758.
    CrossRefPubMed
  113. Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016; 316(12): 1279–1288.
    CrossRefPubMed
  114. Purrucker JC, Wolf M, Haas K, et al. Safety of endovascular thrombectomy in patients receiving non-vitamin K antagonist oral anticoagulants. Stroke. 2016; 47(4): 1127–1130.
    CrossRefPubMed
  115. Wahlgren N, Moreira T, Michel P, et al. Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. Int J Stroke. 2016; 11(1): 134–147.
    CrossRefPubMed
  116. Deharo JC, Sciaraffia E, Leclercq C, et al. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). Europace. 2016; 18(5): 778–784.
    CrossRefPubMed
  117. Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014; 35(28): 1888–1896.
    CrossRefPubMed
  118. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015; 373(9): 823–833.
    CrossRefPubMed
  119. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Interv Card Electrophysiol. 2017; 50(1): 1–55.
    CrossRef
  120. Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke. 2012; 43(1): 265–270.
    CrossRefPubMed
  121. Douketis JD, Spyropoulos AC, Anderson JM, et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017; 117(12): 2415–2424.
    CrossRefPubMed
  122. Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(3): 623–627.
    CrossRefPubMed
  123. Albaladejo P, Bonhomme F, Blais N, et al. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med. 2017; 36(1): 73–76.
    CrossRefPubMed
  124. Cocco G, Amiet P, Jerie P. Anti-thromboembolic strategies in atrial fibrillation. Cardiol J. 2016; 23(2): 211–223.
    CrossRefPubMed
  125. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015; 169(4): 472–8.e5.
    CrossRefPubMed
  126. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
    CrossRefPubMed
  127. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373(21): 2038–2047.
    CrossRefPubMed
  128. Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018; 391(10115): 41–50.
    CrossRef
  129. Kupczynska K, Kasprzak JD, Michalski BW, et al. The impact of the latest echocardiographic chamber quantification recommendations on the prediction of left atrial appendage thrombus presence by transthoracic echocardiography. Acta Cardiol. 2018; 73(1): 91–95.
    CrossRefPubMed
  130. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23): e199–e267.
    CrossRef
  131. Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015; 17(1): 18–23.
    CrossRefPubMed
  132. Grönberg T, Hartikainen JEK, Nuotio I, et al. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). Am J Cardiol. 2016; 117(8): 1294–1298.
    CrossRefPubMed
  133. Nuotio I, Hartikainen JEK, Grönberg T, et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014; 312(6): 647–649.
    CrossRefPubMed
  134. Lip GYH, Hammerstingl C, Marin F, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016; 178: 126–134.
    CrossRefPubMed
  135. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
    CrossRefPubMed
  136. Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016; 5(5).
    CrossRefPubMed
  137. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999; 159(7): 677–685.
    CrossRef
  138. Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018; 131(3): 269–275.e2.
    CrossRefPubMed
  139. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016; 68(11): 1169–1178.
    CrossRefPubMed
  140. Tricco AC, Thomas SM, Veroniki AA, et al. Comparisons of Interventions for Preventing Falls in Older Adults: A Systematic Review and Meta-analysis. JAMA. 2017; 318(17): 1687–1699.
    CrossRefPubMed
  141. Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018; 39(6): 453–460.
    CrossRefPubMed
  142. Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia? Europace. 2018; 20(3): 408–419.
    CrossRefPubMed
  143. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000; 278(5): F817–F822.
    CrossRefPubMed
  144. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(6): 1308–1313.
    CrossRefPubMed
  145. Sandhu RK, Ezekowitz J, Andersson U, et al. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016; 37(38): 2869–2878.
    CrossRefPubMed
  146. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017; 106(8): 565–572.
    CrossRefPubMed
  147. Stefanidou M, Das RR, Beiser AS, et al. Incidence of seizures following initial ischemic stroke in a community-based cohort: The Framingham Heart Study. Seizure. 2017; 47: 105–110.
    CrossRefPubMed
  148. Beghi E, D'Alessandro R, Beretta S, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology. 2011; 77(20): 1785–1793.
    CrossRefPubMed
  149. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
    CrossRefPubMed
  150. Brunetti ND, Gesuete E, De Gennaro L, et al. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. Int J Cardiol. 2017; 230: 214–221.
    CrossRefPubMed
  151. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014; 19(1): 82–93.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note